Drug Free Solution, Inc.
DSOL · OTC
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.07 | 0.00 | 1.86 |
| FCF Yield | 0.00% | 0.00% | 0.00% | -0.36% |
| EV / EBITDA | 0.00 | 0.00 | 0.00 | -82.76 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 0.00% | 501.18% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.27 | 0.28 | 0.33 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | – |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.14% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |